Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Phase 1/2
18–65
2 sites in KS, MO
About this study
This Phase 1/Phase 2 study is testing Bendamustine in people with multiple sclerosis. The primary outcome being measured is To assess the safety and tolerability of TRX319 infusion in subjects with Primary Progressive or Secondary Progressive Multiple Sclerosis.
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
bendamustine
Primary: To assess the safety and tolerability of TRX319 infusion in subjects with Primary Progressive or Secondary Progressive Multiple Sclerosis.
Secondary: To evaluate disease response, as measured by the Neurostatus Expanded Disability Status Scale (EDSS), To evaluate the effects of TRX319 on disease progression/reactivation by gadolinium-enhancing MRI
Neurology